Sotrovimab

Sotrovimab is a monoclonal antibody designed for the treatment of COVID-19. It was developed by Vir Biotechnology and GlaxoSmithKline (GSK). The drug is also known by its developmental code name, VIR-7831.

Etymology[edit | edit source]

The name "Sotrovimab" is derived from the drug's function. "Sotrovi" is a reference to the drug's target, the SARS-CoV-2 virus, and "mab" is a common suffix for monoclonal antibodies.

Mechanism of Action[edit | edit source]

Sotrovimab works by binding to the spike protein of the SARS-CoV-2 virus, preventing the virus from entering human cells. This mechanism of action is similar to other monoclonal antibodies used in the treatment of COVID-19, such as Bamlanivimab and Etesevimab.

Clinical Trials and Authorization[edit | edit source]

Sotrovimab was tested in the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial. Based on the results of this trial, the drug received emergency use authorization from the U.S. Food and Drug Administration (FDA) in May 2021.

Side Effects[edit | edit source]

Common side effects of Sotrovimab include rash, diarrhea, and nausea. Severe side effects are rare but can include allergic reactions.

See Also[edit | edit source]

Sotrovimab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.